Vaccine site inflammation potentiates idiotype DNAvaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity

Hong Qin, Soung Chul Cha, Sattva S. Neelapu, Yanyan Lou, Jinsong Wei, Yong Jun Liu, Larry W. Kwak

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Lymphoma idiotype protein vaccines have shown therapeutic potential in previous clinical studies, and results from a completed pivotal, phase 3 controlled trial are promising. However, streamlined production of these patient-specific vaccines is required for eventual clinical application. Here, we show that second-generation, chemokine-fused idiotype DNA vaccines, when combined with myotoxins that induced sterile inflammation with recruitment of antigen-presenting cells at vaccination sites, were exceptional in their ability to provoke memory antitumor immunity in mice, compared with several TLR agonists. The combined vaccination strategy elicited both antigen-specific T-cell responses and humoral immunity. Unexpectedly, vaccine-induced tumor protection was intact in B cell - deficient mice but was abrogated completely by T-cell depletion in vivo, suggesting T-cell dependence. Furthermore, the optimal effect of myotoxins was observed with fusion vaccines that specifically targeted antigen delivery to antigen-presenting cells and not with vaccines lacking a targeting moiety, suggesting that the rational vaccine design will require combination strategies with novel, proinflammatory agents and highly optimized molecular vaccine constructs. These studies also challenge the paradigm that antibody responses are the primary of idiotype-specific antitumor effects and support the optimization of idiotype vaccines designed to induce primarily T-cell immunity.

Original languageEnglish (US)
Pages (from-to)4142-4149
Number of pages8
JournalBlood
Volume114
Issue number19
DOIs
StatePublished - Nov 5 2009
Externally publishedYes

Fingerprint

T-cells
Immunity
B-Lymphocytes
Vaccines
Cells
Inflammation
T-Lymphocytes
Antigen-Presenting Cells
Vaccination
Therapeutics
Antigens
Cancer Vaccines
Synthetic Vaccines
DNA Vaccines
Aptitude
Humoral Immunity
Chemokines
Antibody Formation
Lymphoma
Tumors

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Vaccine site inflammation potentiates idiotype DNAvaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. / Qin, Hong; Cha, Soung Chul; Neelapu, Sattva S.; Lou, Yanyan; Wei, Jinsong; Liu, Yong Jun; Kwak, Larry W.

In: Blood, Vol. 114, No. 19, 05.11.2009, p. 4142-4149.

Research output: Contribution to journalArticle

Qin, Hong ; Cha, Soung Chul ; Neelapu, Sattva S. ; Lou, Yanyan ; Wei, Jinsong ; Liu, Yong Jun ; Kwak, Larry W. / Vaccine site inflammation potentiates idiotype DNAvaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. In: Blood. 2009 ; Vol. 114, No. 19. pp. 4142-4149.
@article{4b34c3a7e1c541b9a490d7486312b240,
title = "Vaccine site inflammation potentiates idiotype DNAvaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity",
abstract = "Lymphoma idiotype protein vaccines have shown therapeutic potential in previous clinical studies, and results from a completed pivotal, phase 3 controlled trial are promising. However, streamlined production of these patient-specific vaccines is required for eventual clinical application. Here, we show that second-generation, chemokine-fused idiotype DNA vaccines, when combined with myotoxins that induced sterile inflammation with recruitment of antigen-presenting cells at vaccination sites, were exceptional in their ability to provoke memory antitumor immunity in mice, compared with several TLR agonists. The combined vaccination strategy elicited both antigen-specific T-cell responses and humoral immunity. Unexpectedly, vaccine-induced tumor protection was intact in B cell - deficient mice but was abrogated completely by T-cell depletion in vivo, suggesting T-cell dependence. Furthermore, the optimal effect of myotoxins was observed with fusion vaccines that specifically targeted antigen delivery to antigen-presenting cells and not with vaccines lacking a targeting moiety, suggesting that the rational vaccine design will require combination strategies with novel, proinflammatory agents and highly optimized molecular vaccine constructs. These studies also challenge the paradigm that antibody responses are the primary of idiotype-specific antitumor effects and support the optimization of idiotype vaccines designed to induce primarily T-cell immunity.",
author = "Hong Qin and Cha, {Soung Chul} and Neelapu, {Sattva S.} and Yanyan Lou and Jinsong Wei and Liu, {Yong Jun} and Kwak, {Larry W.}",
year = "2009",
month = "11",
day = "5",
doi = "10.1182/blood-2009-05-219683",
language = "English (US)",
volume = "114",
pages = "4142--4149",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Vaccine site inflammation potentiates idiotype DNAvaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity

AU - Qin, Hong

AU - Cha, Soung Chul

AU - Neelapu, Sattva S.

AU - Lou, Yanyan

AU - Wei, Jinsong

AU - Liu, Yong Jun

AU - Kwak, Larry W.

PY - 2009/11/5

Y1 - 2009/11/5

N2 - Lymphoma idiotype protein vaccines have shown therapeutic potential in previous clinical studies, and results from a completed pivotal, phase 3 controlled trial are promising. However, streamlined production of these patient-specific vaccines is required for eventual clinical application. Here, we show that second-generation, chemokine-fused idiotype DNA vaccines, when combined with myotoxins that induced sterile inflammation with recruitment of antigen-presenting cells at vaccination sites, were exceptional in their ability to provoke memory antitumor immunity in mice, compared with several TLR agonists. The combined vaccination strategy elicited both antigen-specific T-cell responses and humoral immunity. Unexpectedly, vaccine-induced tumor protection was intact in B cell - deficient mice but was abrogated completely by T-cell depletion in vivo, suggesting T-cell dependence. Furthermore, the optimal effect of myotoxins was observed with fusion vaccines that specifically targeted antigen delivery to antigen-presenting cells and not with vaccines lacking a targeting moiety, suggesting that the rational vaccine design will require combination strategies with novel, proinflammatory agents and highly optimized molecular vaccine constructs. These studies also challenge the paradigm that antibody responses are the primary of idiotype-specific antitumor effects and support the optimization of idiotype vaccines designed to induce primarily T-cell immunity.

AB - Lymphoma idiotype protein vaccines have shown therapeutic potential in previous clinical studies, and results from a completed pivotal, phase 3 controlled trial are promising. However, streamlined production of these patient-specific vaccines is required for eventual clinical application. Here, we show that second-generation, chemokine-fused idiotype DNA vaccines, when combined with myotoxins that induced sterile inflammation with recruitment of antigen-presenting cells at vaccination sites, were exceptional in their ability to provoke memory antitumor immunity in mice, compared with several TLR agonists. The combined vaccination strategy elicited both antigen-specific T-cell responses and humoral immunity. Unexpectedly, vaccine-induced tumor protection was intact in B cell - deficient mice but was abrogated completely by T-cell depletion in vivo, suggesting T-cell dependence. Furthermore, the optimal effect of myotoxins was observed with fusion vaccines that specifically targeted antigen delivery to antigen-presenting cells and not with vaccines lacking a targeting moiety, suggesting that the rational vaccine design will require combination strategies with novel, proinflammatory agents and highly optimized molecular vaccine constructs. These studies also challenge the paradigm that antibody responses are the primary of idiotype-specific antitumor effects and support the optimization of idiotype vaccines designed to induce primarily T-cell immunity.

UR - http://www.scopus.com/inward/record.url?scp=77950539903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950539903&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-05-219683

DO - 10.1182/blood-2009-05-219683

M3 - Article

C2 - 19749091

AN - SCOPUS:77950539903

VL - 114

SP - 4142

EP - 4149

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -